15/10/2025
CAR-T therapy: turning refractory disease into remission.
When you examine the PET-CT images, the earlier scan shows all those dark, glowing spots — active lymphoma deposits. Most of the disease was outside the lymph nodes, affecting the kidneys and bones. Even an autologous transplant doesn’t often lead to long remissions in this setting. But just four weeks after CAR-T therapy, the follow-up scan shows no active disease at all. This patient had relapsed, refractory high-grade B-cell lymphoma after R-CHOP, R-ICE, radiotherapy, and Polatuzumab. With no other options remaining, we proceeded with CAR-T (Qartemi, Immuneel). Four weeks later, he’s in complete metabolic remission. This was our first CAR-T therapy at Omega Hospitals — and hopefully just the beginning. CAR-T doesn’t work for everyone, but when it does, it can completely change the story. It’s moments like these that remind us what science, persistence, and teamwork can accomplish.
